Abstract

Genetic variants of <i>hENT-1</i> to predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Genetic variants of DNA repair-related genes predict efficacy of TAS-102 in patients with refractory metastatic colorectal cancer
T Yamaguchi ... Y Ning
Annals of Oncology | VOL. 28
T Yamaguchi, et. al.T Yamaguchi ... Y Ning
01 May 2017
Factors associated with efficacy of TAS-102 in patients with refractory metastatic colorectal cancer (mCRC).
Peter Grell ... Tomas Buchler
Journal of Clinical Oncology | VOL. 36
Peter Grell, et. al.Peter Grell ... Tomas Buchler
01 Feb 2018
A phase I clinical trial of trametinib in combination with TAS-102 in patients with chemotherapy-resistant RAS-mutated (PIK3CA/PTEN-wild type) metastatic colorectal cancer.
Chongkai Wang ... Marwan Fakih
Journal of Clinical Oncology | VOL. 40
Chongkai Wang, et. al.Chongkai Wang ... Marwan Fakih
01 Jun 2022
Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.
Filippo Pietrantonio ... Alessandra Raimondi
Tumori | VOL. 107
Filippo Pietrantonio, et. al.Filippo Pietrantonio ... Alessandra Raimondi
06 Oct 2020
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes
Cristina Astrid Tentori ... Fabio Ciceri
Journal of Clinical Oncology | VOL. -
Cristina Astrid Tentori, et. al.Cristina Astrid Tentori ... Fabio Ciceri
09 May 2024
Addressing Disability in Cancer Survivors
Rachelle Brick ... Emily S Tonorezos
Journal of Clinical Oncology | VOL. -
Rachelle Brick, et. al.Rachelle Brick ... Emily S Tonorezos
09 May 2024
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study
Susanna Hegewisch-Becker ... Niall C Tebbutt
Journal of Clinical Oncology | VOL. -
Susanna Hegewisch-Becker, et. al.Susanna Hegewisch-Becker ... Niall C Tebbutt
09 May 2024
A pivotal phase 2 single-arm study of glecirasib (JAB-21822) in patients with NSCLC harboring KRAS G12C mutation.
Yuankai Shi ... Zhengbo Song
Journal of Clinical Oncology | VOL. 42
Yuankai Shi, et. al.Yuankai Shi ... Zhengbo Song
30 Apr 2024
View more papers